T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

U.K. biotech startup T-Therapeutics raised $133 million in Series B financing on November 5, 2026, to transition into a clinical-stage company. Co-led by Advent Life Sciences and British Business Bank with support from Eli Lilly, Johnson & Johnson, Merck KGaA, and Sanofi, the round will fund proof-of-concept testing for lead bispecific candidates TTX-008 for solid tumors and TTX-018 for autoimmune diseases.

T-Therapeutics raises $133M Series B

• ▪T-Therapeutics previously expanded its Series A financing round by $32 million in 2025
• ▪U.K. biotech startup T-Therapeutics raised a $133 million Series B financing round on November 5, 2026, to advance its cancer and autoimmune drug candidates into clinical trials
• ▪The Series B round for T-Therapeutics was co-led by Advent Life Sciences and British Business Bank, with participation from Eli Lilly, Johnson & Johnson's venture arm, Samsara BioCapital, and Sofinnova Partners

Advent Life Sciences on T-Cell engagers

• ▪Advent Life Sciences General Partner Dominic Schmidt stated that T-cell engagers have been held back in solid tumors by a lack of appropriate targets
• ▪Advent Life Sciences General Partner Dominic Schmidt stated that T-Therapeutics can access previously unreachable targets with a markedly improved safety profile for solid tumors

Expansion of T-Cell engager therapies

• ▪U.S. regulators have approved ten T-cell engager therapies, primarily for blood cancers
• ▪Drugmakers have recently sought to replicate the success of T-cell engagers in solid tumors using technical advances designed to address known weaknesses